New research at Saint Louis University shows physicians do not talk to patients about the psychosocial impact and long-term risks of implanting cardioverter defibrillators (ICDs) to treat irregular… read more.
For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in liver enzymes affect the drug’s effectiveness and… read more.
Taken from The Lancet – by Bruce Sylvester – Patients with cough treated with amoxicillin do not recover significantly more quickly or have significantly fewer symptoms than other… read more.
Egg allergic children did not have adverse reactions to single dose of influenza vaccine in multi-center study
Social adversity and ethnicity linked to significantly poorer test scores in Key Stages 1-3.
Encouraging safety and efficacy data on novel and emerging therapies presented at the 54th Annual Meeting of the American Society of Haematology (ASH) signal an important step forward… read more.
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3… read more.
Data demonstrate superior patient outcomes with B-R in first-line treatment of iNHL and MCL, compared with current standard of care.
by Bruce Sylvester – FDA Highlights – According to a study published online on September 7, 2012 in the American Journal of Respiratory and Critical Care Medicine, treatment… read more.
by Gary Finnegan – World Health Matters (Canada) – Austerity measures introduced by European governments and the deepening threat of insolvency faced by the US Medicare system have… read more.
by Marybeth Burke – Regorafenib significantly improved progression-free survival (PFS) and disease control rate (DCR) in patients with advanced gastrointestinal stromal tumours (GIST) that progress due to resistance… read more.
by Marybeth Burke – The investigational agent trastuzumab emtansine (T-DM1) demonstrated improved efficacy over capecitibine plus lapatinib and improved progression-free survival (PFS) in women with HER2-positive locally advanced… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
